CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads to the creation of first in class Probody therapeutics. These therapeutics are meant to overcome safety and efficacy problems encountered by the antibodies that are currently used in immunotherapy.

A simple explanation for the potential advantages of the Probody therapies is that these drugs remain inactive until they are activated only by proteases . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.